PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
231.81%
G&A growth above 1.5x CRVO's 37.03%. Michael Burry would check for operational inefficiency.
No Data
No Data available this quarter, please select a different quarter.
-559.42%
Other expenses reduction while CRVO shows 100.00% growth. Joel Greenblatt would examine efficiency.
182.89%
Operating expenses growth 50-75% of CRVO's 251.41%. Bruce Berkowitz would examine efficiency.
182.89%
Total costs growth above 1.5x CRVO's 15.98%. Michael Burry would check for inefficiency.
10.64%
Interest expense change of 10.64% while CRVO maintains costs. Bruce Berkowitz would investigate control.
No Data
No Data available this quarter, please select a different quarter.
-245.34%
Both companies show EBITDA decline. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
-249.64%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-56.01%
Tax expense reduction while CRVO shows 0.00% growth. Joel Greenblatt would examine advantage.
-146.74%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
-145.19%
Both companies show declining EPS. Martin Whitman would check industry conditions.
-145.19%
Both companies show declining diluted EPS. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.